5'-Hexyne phosphoramidite
Compound hex-5-yn-1-ol (1.4 mL) was dissolved with 10 mL dichloromethane and N,N-diisopropylamine (1.82 mL) was added to the solution. In a separate flask under anhydrous conditions, the phosphinylating reagent bis-(N,N-diisopropylamino)-cyanoethylphosphine (1.5 equiv.) was diluted with dichloromethane (2 mL per mmol phosphine) and a solution of 0.45 M 1H-tetrazole in MeCN (0.5 equiv.) was added and shaken for 5 min. Next, the solution of activated phosphinylating reagent was added to the well-stirred solution of compound hex-5-yn-1-ol at room temperature and stirred at room temperature until the reaction is complete by TLC analysis. To quench the excess phosphine ethanol was added and the reaction mixture was stirred for additional 30 minutes and dried on the rotary evaporator. The product was purified on silica gel to give 0.8 g of 5'-Hexyne phosphoramidite.
31
P NMR (CDCl 3 , 121.5 mHz): 147.0 ppm (s).
RNA synthesis
Synthetic RNAs were synthesized on a 1-µmol scale using a MerMade 12 synthesizer through 2'-ACE chemistry procedures. The 2′-ACE-phosphoramidites (rU, iBu-rA, iBu-rG, and Ac-rC) and 5'-hexyne phosphoramidite (0.1 M in anhydrous acetonitrile) was coupled to the growing polyribonucleotide chain using 5-ethylthio-1H-tetrazole (0.5 M in anhydrous acetonitrile) as the activator. Once the synthesis of the polyribonucleotide chain was completed, the phosphate protecting groups were removed from the immobilized polyribonucleotide by treatment with disodium 2-carbamoyl-2-cyanoethylene-1,1-dithiolate-trihydrate in DMF for 15 min. The support was washed with water (5 mL), and the column was flushed with argon gas for 5 min to dry the support. The support was then transferred to a 2-ml Eppendorf tube, and the polyribonucleotide was cleaved from the support and the exocyclic amine protecting groups were removed by treatment with 1:3 (v/v) tert-butylamine:water for 6 h at 55 °C. The sample was cooled to room temperature, filtered, and lyophilized to obtain the crude 2'-ACE-protected polyribonucleotide. For RNA tracr-2, cr-2, or sg-2, the 2′-ACE group was removed with acetate/TEMED using the protocol recommended by Dharmacon. The oligonucleotides were desalted by ethanol precipitation. The RNAs were characterized by UPLC and ESI-MS analysis. For RNA cr-3, azidoacetic acid NHS ester (5 mg, Click Chemistry Tools) in DMF was added post-synthetically to the freeze dried 3'-aminoalkyl-modified oligonucleotide (2'-ACE protected cr-3, 820 nmol) in Na 2 CO 3 /NaHCO 3 buffer. The 3'-azide-labeled oligonucleotide (2'-ACE protected cr-1, 203 nmol) was obtained by reverse-phase HPLC purification and desalting.
Click conjugation 5'-Hexyne-modified oligonucleotide (2'-ACE protected tracr-1) (50 nmol) was dissolved in water and 2M TEAA buffer (pH 7.0). 3'-Azide-labeled oligonucleotide (2'-ACE protected cr-1) (75 nmol, 10 mM stock solution in DMSO) was then added. A stock 5 mM solution of ascorbic acid (175 uL) was added followed by degassing the solution with argon. A pre-made solution (10 mM in 55% DMSO) of Cu(II)-TBTA (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) (87 uL) was added to the mixture. The mixture was allowed to react at room temperature overnight. The conjugated oligonucleotide (2'-ACE protected sg-1) was precipitated with acetone. The pellet was washed with acetone, dried, and purified by reverse-phase HPLC. 2'-ACE groups were removed by adding Dharmacon's 2'-deprotection buffer (100 mM acetic acid-TEMED, pH 3.4-3.8) with 30 minute incubation at room temperature. The conjugated RNA oligonucleotide (sg-1, 56 nmol) was desalted by ethanol precipitation and characterized by ESI-MS analysis.
Creation of Cas9 stable cell lines U2OS cells (ATCC® Number: HTB-96) were seeded at 100,000 cells per well in a 24-well plate (Costar, #3524). The following day, cells were transduced with 3 μL of Cas9 lentiviral particles (rough estimate of viral titer: 1 × 10 6 viral particles per mL). The cells were expanded into a 6-well plate (Thermo Scientific, #140675) 72 hours post-transduction. After a 48 hour recovery and expansion period, the cells were exposed to 2 μg/mL of puromycin (Invivogen, . Cells that survived the selection were harvested and utilized in the following experiments and are referred to as U2OS-Cas9 cells.
Lipid transfection
U2OS-Cas9 cells were seeded in a 96-well plate at 10,000 cells per well. Single guide RNA, crRNA, and tracrRNA were individually resuspended in 10 mM Tris-HCl (pH7.5), to 100 μM. sgRNA was further diluted to 2.5 μM using 10 mM Tris-HCl (pH7.5). crRNA and tracrRNA were combined and further diluted to 2.5 μM using 10 mM Tris-HCl (pH7.5). A final concentration of 25 nM sgRNA or crRNA:tracrRNA complex (25 nM of each crRNA and tracrRNA) was used for transfection. Cells were transfected with 0.4 µL/well DharmaFECT Duo Transfection Reagent (Dharmacon Cat #T-2010-03) using 25 nM crRNA:tracrRNA complex.
Genomic DNA isolation and DNA mismatch detection assay Genomic DNA was isolated 72 hours post-transfection by direct lysis of the cells in Phusion™ HF buffer (Thermo Scientific Cat #F-518L) proteinase K (Thermo Scientific Cat #EO0491) and RNase A (Thermo Scientific Cat #EN0531) for 15 minutes at 56 °C followed by heat inactivation at 95 °C for 5 minutes. PCR was performed with primers flanking the CRISPR targeting sites. PCR products (500 ng) were treated with T7 endonuclease I (T7EI; NEB Cat #M0302L) for 25 minutes at 37 °C and the samples were
